このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Guangdong Hybribio BiotechLtd 将来の成長

Future 基準チェック /36

Guangdong Hybribio BiotechLtd は、年間 35.4% の収益が増加すると予測されています。EPSは年間増加すると予想されます33.3%。

主要情報

35.4%

収益成長率

33.3%

EPS成長率

Biotechs 収益成長	32.4%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	03 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065

May 22

There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings

May 03

業績と収益の成長予測

SZSE:300639 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2024	985	61	-92	186	N/A
12/31/2023	1,104	140	-66	320	N/A
9/30/2023	2,189	410	195	792	N/A
6/30/2023	3,361	871	313	1,012	N/A
3/31/2023	4,388	1,292	543	1,259	N/A
1/1/2023	5,597	1,726	575	1,309	N/A
9/30/2022	4,940	1,693	360	1,080	N/A
6/30/2022	4,217	1,439	294	994	N/A
3/31/2022	3,574	1,180	91	801	N/A
1/1/2022	2,673	852	-10	631	N/A
9/30/2021	2,429	736	-110	449	N/A
6/30/2021	2,148	625	-181	276	N/A
3/31/2021	1,814	515	-78	286	N/A
12/31/2020	1,354	363	24	311	N/A
9/30/2020	1,129	316	19	184	N/A
6/30/2020	918	216	-75	135	N/A
3/31/2020	742	150	-106	89	N/A
12/31/2019	729	147	-84	113	N/A
9/30/2019	693	141	-86	104	N/A
6/30/2019	648	128	-58	89	N/A
3/31/2019	610	119	-62	90	N/A
12/31/2018	580	114	-64	80	N/A
9/30/2018	548	107	-65	68	N/A
6/30/2018	518	102	-13	73	N/A
3/31/2018	499	96	-4	72	N/A
12/31/2017	479	93	N/A	79	N/A
9/30/2017	455	89	N/A	79	N/A
6/30/2017	431	80	N/A	59	N/A
3/31/2017	411	77	N/A	67	N/A
12/31/2016	398	76	N/A	64	N/A
12/31/2015	345	65	N/A	48	N/A
12/31/2014	264	63	N/A	35	N/A
12/31/2013	183	29	N/A	23	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 300639の予測収益成長率 (年間35.4% ) は貯蓄率 ( 2.9% ) を上回っています。

収益対市場: 300639の収益 ( 35.4% ) はCN市場 ( 22.7% ) よりも速いペースで成長すると予測されています。

高成長収益: 300639の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 300639の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 300639の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 300639の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Guangdong Hybribio BiotechLtd 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Recent updates

Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065

Dividend of CN¥0.065 announced

There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, May 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 24% overvalued

Guangdong Hybribio Biotech Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) announces an Equity Buyback for CNY 60 million worth of its shares.

Investor sentiment deteriorates as stock falls 16%

Guangdong Hybribio Biotech Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released: EPS: CN¥0.076 (vs CN¥0.78 in 3Q 2022)

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.088 (vs CN¥0.73 in 2Q 2022)

Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Guangdong Hybribio Biotech Co.,Ltd. Announces Cash Dividend on A Shares for Year 2022, Payable on May 22, 2023

Investor sentiment deteriorates as stock falls 19%

Full year 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on October 10, 2022.

Third quarter 2022 earnings released: EPS: CN¥1.17 (vs CN¥0.59 in 3Q 2021)

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Announces Director Appointments

Second quarter 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.50 in 2Q 2021)

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Declares Dividend Implementation of A Shares for the Year 2021, Payable on April 29, 2022

Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Guangdong Hybribio Biotech Co.,Ltd. Announces Final Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Now 22% undervalued

Investor sentiment improved over the past week

Now 22% undervalued

Now 21% undervalued

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.88 (vs CN¥0.54 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.75 (vs CN¥0.43 in 2Q 2020)

Investor sentiment improved over the past week

Guangdong Hybribio Biotech Co.,Ltd. Declares Dividend Implementation of A Shares for the Year 2020, Payable on May 28, 2021

Guangdong Hybribio Biotech Co.,Ltd. Approves Profit Distribution for 2020

First quarter 2021 earnings released: EPS CN¥0.73 (vs CN¥0.09 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥0.70 in FY 2019)

New 90-day low: CN¥32.33

Guangdong Hybribio Biotech Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 15, 2021

New 90-day low: CN¥33.91

Investor sentiment deteriorated over the past week

New 90-day low: CN¥42.94

Third quarter earnings released

Third quarter earnings released

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2020 Results on Oct 23, 2020

First half earnings released

Guangdong Hybribio Biotech Co.,Ltd. to Report First Half, 2020 Results on Aug 15, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘